ReviewTranslational cancer research2026
PHGDH in cancer: a narrative review of its functions beyond serine metabolism.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Metabolic reprogramming represents a fundamental characteristic of cancer, with dysregulation of serine metabolism being increasingly recognized as a critical contributor to tumor transformation and progression. Cancer cells acquire serine through two major pathways: exogenous uptake from food and endogenous synthesis via the Methods: We comprehensively reviewed the current literature on PHGDH in cancer by searching PubMed and Web of Science for English-language publications available up to February 2026. The evidence was critically synthesized to summarize the regulatory mechanisms, emerging non-canonical functions, and therapeutic implications of PHGDH. Key Content and Findings: We summarize the metabolic functions and regulatory mechanisms governing PHGDH expression and activity in cancer and comprehensively review its recently identified non-canonical functions beyond serine biosynthesis. Emerging evidence demonstrates that PHGDH exerts diverse metabolism-independent activities, including regulation of gene transcription, RNA metabolism and protein interactions, thereby contributing to tumor progression, immune modulation, and therapeutic responses. We further discuss the current landscape of PHGDH-targeted therapeutic strategies, including catalytic inhibitors and emerging approaches aimed at disrupting its non-metabolic functions, together with their opportunities and current limitations. Conclusions: PHGDH is not only a metabolic enzyme but also a multifunctional regulator of tumor biology. Recognition of its non-canonical activities substantially expands our understanding of serine metabolism in cancer and provides new perspectives for precision oncology. Future studies should clarify the molecular mechanisms governing PHGDH's context-dependent functions, define its interaction networks and subcellular regulation, and facilitate the development of next-generation therapeutic strategies targeting both its metabolic and non-metabolic activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.